Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 395-401

  Dai, Hongying ^a,c   Zhang, Ping ^b   Zhao, Shuping ^c   Zhang, Jingjing ^c   Wang, Bo ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

Endometrial adenocarcinoma; Estradiol; Ishikawa cells; Raloxifene; Tamoxifen; Vascular endothelial growth factor

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RESPONSIVE FINGER PROTEIN; GENE PRODUCT; MESSENGER RNA; RALOXIFENE; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG; VASCULOTROPIN; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRANSCRIPTION FACTOR; TRIM25 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; VASCULOTROPIN A;

ARTICLE; CARCINOMA CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DRUG EFFECT; ENDOMETRIUM TUMOR; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE EXPRESSION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RALOXIFENE; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TAMOXIFEN; TRANSCRIPTION FACTORS; TRANSFECTION; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 62849086213     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000235     Document Type: Article

References (38)

1. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Sideri M and Pecorelli S: Carcinoma of the corpus uteri. J Epidemiol Biostat 6: 47-86, 2001.
2. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL and Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527-537, 1994.
3. Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A and Cummings S: Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 104: 837-844, 2004.
4. Dutertre M and Smith CL: Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 295: 431-437, 2000.
5. Orimo A, Inoue S, Ikeda K, Noji S and Muramatsu M: Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. J Biol Chem 270: 24406-24413, 1995.
6. Inoue S, Urano T, Ogawa S, Saito T, Orimo K, Hosoi T, Ouchi Y and Muramatsu M: Molecular cloning of rat efp: expression and regulation in primary osteoblasts. Biochem Biophys Res Commun 261: 412-418, 1999.
7. Orimo A, Inoue S, Minowa O, Tominaga N, Tomioka Y, Sato M, Kuno J, Hiroi H, Shimizu Y, Suzuki M, Noda T, and Muramatsu M: Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor. Proc Natl Acad Sci USA 96: 2027-2032, 1999.
8. Chao JI, Kuo PC and Hsu TS: Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem 279: 20267-20276, 2004.
9. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME and Shaul PW: Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103: 401-406, 1999.
10. Seki N, Kodama J, Hongo A, Miyagi Y, Yoshinouchi M and Kudo T: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer. Eur J Cancer 36: 68-73, 2000.
11. Kook HS, Hyun SL, Bongnam J, Hyun MK, Jung HC, Sung JP, Il HC, Hern KL and Suhn YI: Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-κB activation. Cancer Res 64: 6482-6488, 2004.
12. Hervé MA, Meduri G, Petit FG, Domet TS, Lazennec G, Mourah S and Perrot-Applanat M: Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus. J Endocrinol 188: 91-99, 2006.
13. Nishida M, Kasahara K, Kaneko M, Iwasaki H and Hayashi K: Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi 37: 1103-1111, 1985.
14. Mahavni V and Sood AK: Hormone replacement therapy and cancer risk. Curr Opin Oncol 13: 384-389, 2001.
15. Jun W, Yuko K, Norihisa S, Isao O and Hiroyuka K: Stimulatory effect of estrogen on the growth of endometrial cancer cells is regulated by cell-cycle regulators. J Steroid Biochem Mol Biol 107: 163-171, 2007.
16. Zhu L and Pollard JW: Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. Proc Natl Acad Sci USA 104: 15847-15851, 2007.
17. Suga S, Kato K, Ohgami T, Yamayoshi A, Adachi S, Asanoma K, Yamaguchi S, Arima T, Kinoshita K and Wake N: An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol 105: 341-350, 2007.
18. Guo RX, Wei LH, Tu Z, Sun PM, Wang JL, Zhao D, Li XP and Tang JM: 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol 99: 9-18, 2006.
19. Mazumdar A and Kumar R: Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett 535: 6-10, 2003.
20. Cano A and Hermenegildo C: The endometrial effects of SERMs. Hum Reprod Update 6: 244-254, 2000.
21. Hibner M, Magrina JF, Lefler SR, Cornella JL, Pizarro AR and Loftus JC: Effects of raloxifene hydrochloride on endometrial cancer cells in vitro. Gynecol Oncol 93: 642-646, 2004.
22. Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H and Hayashi S: Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol 192: 93-104, 2002.
23. Leblanc K, Sexton E, Parent S, Bélanger G, Déry MC, Boucher V and Asselin E: Effects of 4-hydroxytamoxifen, raloxifene and ICI182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. Int J Oncol 30: 477-487, 2007.
24. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM and McDonnell DP: Peptide antagonists of the human estrogen receptor. Science 285: 744-746, 1999.
25. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP and Fowlkes DM: Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci USA 96: 3999-4004, 1999.
26. Emely CR and Stephen S: 17ß-Estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context. J Steroid Biochem Mol Biol 84: 23-31, 2003.
27. Jones PS, Parrott E and White IN: Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent. J Biol Chem 274: 32008-32014, 1999.
28. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J and Nilsson S: Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 54: 105-112, 1998.
29. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ and Scanlan TS: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510, 1997.
30. Inoue S, Orimo A, Hosoi T, Kondo S, Toyoshima H, Kondo T, Ikegami A, Ouchi Y, Orimo H and Muramatsu M: Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Nat Acad Sci USA 90: 11117-11121, 1993.
31. Suzuki T, Urano T, Tsukui T, Horie-Inoue K, Moriya T, Ishida T, Muramatsu M, Ouchi Y, Sasano H and Inoue S: Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clin Cancer Res 11: 6148-6154, 2005.
32. Ikeda K, Orimo A, Higashi Y, Muramatsu M and Inoue S: Efp as a primary estrogen-responsive gene in human breast cancer. FEBS 472: 9-13, 2000.
33. Bermont L, Lamielle-Musard F, Chezy E, Weisz A and Adessi GL: 17beta-estradiol inhibits forskolin-induced vascular endothelial growth factor promoter in MCF-7 breast adenocarcinoma cells. J Steroid Biochem Mol Biol 78: 343-349, 2001.
34. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
35. Plate KH, Breier G, Weich HA and Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.
36. Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B and Jordan VC: Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol Oncol 85: 498-506, 2002.
37. Lam PM, Yim SF, Briton-Jones C, Chung TK and Haines C: Raloxifene therapy in postmenopausal women is associated with a significant reduction in the concentration of serum vascular endothelial growth factor. Fertil Steril 81: 393-397, 2004.
38. Mueller MD, Pritts EA, Zaloudek CJ, Dreher E and Taylor RN: Regulation of vascular endothelial growth factor by tamoxifen in vitro and in vivo. Gynecol Obstet Invest 55: 119-124, 2003.